Groww Logo
Home>IPO>Vijaya Diagnostic Centre Ltd.

Vijaya Diagnostic IPO

Vijaya Diagnostic Centre Ltd.

₹14,616 /28 sharesMinimum Investment

IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
BSE & NSE₹531.00₹540.00₹9.00 (1.69%)

IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
1 Sep ‘21 - 3 Sep ‘21₹14,61628₹522 - ₹531
Issue SizeIPO Doc
1895.04Cr
RHP PDF

Subscription Rate As on 03 Sep '21, 5:00 PM

  • Retail Individual Investor
    1.09x
  • Non-Institutional Investor
    1.32x
  • Qualified Institutional Buyers
    13.07x
  • Employees
    0.98x

About Company

Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in southern India, by operating revenue, and also one of the fastest-growing diagnostic chains by revenue for the fiscal year 2020. It offers a one-stop solution for pathology and radiology testing services to its customers through 81 diagnostic centers and 11 reference laboratories across 13 cities and towns in Telangana, Andhra Pradesh and National Capital Region (NCR), and Kolkata as on June 30, 2021.
... Read More
Founded
2002
Managing Director
K Sunil Chandra
Vijaya Diagnostic IPO Review, Date, Price, Details - Upcoming IPO 2021

Strengths & Risks

  • Largest and fastest-growing diagnostic chain with a dominant position in south India according to a CRISIL report.
  • Well-positioned to leverage the high growth in the Indian diagnostics industry.
  • Integrated diagnostics provider that offers a one-stop solution at an affordable price with a focus on superior quality standards.
  • High brand recall driving high individual consumer business share and customer stickiness.
  • Strong technical capabilities, quality infrastructure, and state of the art medical technology with strong IT infrastructure.
  • Dedicated management team with significant industry experience.
  • Business and prospects may be adversely affected if it is unable to maintain and grow its brand name and brand image..
  • Impact of global health epidemics, including the recent COVID-19 outbreak.
  • Any interruptions at its flagship center and other diagnostic centers that may affect its ability to process diagnostic tests.
  • Geographic concentration of its operations in South India.
  • Outstanding legal proceedings involving the company, subsidiaries, and directors.
  • Losses incurred by its group companies in the past.
  • Any failure by third parties in providing testing equipment and reagents as required.
  • Any failure or malfunction of the equipment.
  • Non-compliance with and changes in any of the applicable laws, rules, or regulations, including pricing, safety, health, and environmental laws.
  • Requirement of certain approvals, licenses, registrations, and permits for conducting its business and our inability to obtain, retain or renew them in a timely manner.
  • A highly competitive business environment.

Financials

*All values are in Rs. Cr
No Graph Data To Display
ⓒ 2016-2022 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 2.1.6
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI
ABOUT GROWW